RxDoctor Payments Data

John Snook, MD

Family Medicine · Greenwood, INNPI 1710962840

Payments from drug & device makers

$1,326in general payments, 2019–2025

Across 56 payments — averaging $23.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$289
  • AbbVie$250
  • GSK$167
  • Amgen$157
  • AstraZeneca$125
  • Radius Health, Inc.$118
  • plus $220 from 9 others

What the payments were for

  • Food & beverage$1,29398%
  • Education$332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,326 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$99,904
Medicare patients
294
Services billed
1,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$90,993
TrulicityDulaglutide58$90,889
JanuviaSitagliptin Phosphate27$38,838
OzempicSemaglutide18$29,942
EliquisApixaban19$23,476
MounjaroTirzepatide13$15,510
FarxigaDapagliflozin Propanediol11$13,571
Breo ElliptaFluticasone/Vilanterol12$11,092
Spiriva HandihalerTiotropium Bromide14$10,190
Atorvastatin Calcium773$5,658
VascepaIcosapent Ethyl12$4,537
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$4,404
Omeprazole228$3,341
Levothyroxine Sodium304$3,209
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen149$2,995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$289$106,39971 claims
MerckJanuvia$39$38,83827 claims
Novo NordiskOzempic$33$29,94218 claims
AstraZenecaFarxiga$125$13,57111 claims
GSKBreo Ellipta$167$11,09212 claims
AbbVieSynthroid$250$1,93629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Greenwood

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →